Sygnis Licenses Protein-Protein Interaction Analysis Technology to Systasy | GenomeWeb

NEW YORK (GenomeWeb) – German-Spanish DNA amplification and sequencing firm Sygnis today announced it has signed a patent transfer agreement providing certain rights to its Double Switch technology to Systasy Bioscience.

The Double Switch technology is for the qualitative and quantitative detection of protein-protein interactions, and as part of the deal, Systasy has purchased the patent covering the technology in a split version (Split TEV) for use with its EXTassay platform.

Sygnis retains the rights to Double Switch in its full-length version (Full TEV).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for RNA splicing in genetic variation, and more.

An advocacy group sues the US Food and Drug Administration over redactions of information about advisory committee members, Stat News reports.

Mexico is trying to lure young genomics researchers back home with their own labs, Science reports.

A molecular autopsy has aided a woman's search for why sudden cardiac death has stalked her family, the Wall Street Journal reports.